FDA LabelsFeb 2026
Why Most People Can't Read Their Own Prescription Labels
FDA drug labels are written for healthcare professionals, not patients. We break down what each section actually means and why the language matters.
Articles
Drug transparency, explained.
Plain language breakdowns of how drug data works, what government databases actually contain, and what the numbers mean.
VAERSJan 2026
VAERS Data Gets Misused Constantly. Here's How to Read It Right.
Anyone can submit a VAERS report, and a report alone doesn't prove a vaccine caused a side effect. Understanding how passive reporting works is critical before drawing conclusions.
RecallsJan 2026
The FDA Recall System Has Three Classes. Most People Only Hear About One.
Class I recalls grab headlines, but Class II and III happen far more often. What the classification actually tells you about risk.
Clinical TrialsDec 2025
What Happens in a Phase 3 Clinical Trial
Phase 3 is where a drug proves it works in large groups of people. But the process is more nuanced than 'it passed' or 'it failed.'
IngredientsDec 2025
Inactive Ingredients Aren't Always Harmless
Fillers, dyes, and preservatives can trigger allergic reactions in some patients. A look at which inactive ingredients to watch for and why they're in your medication.
Data InfrastructureNov 2025
How RxNorm Connects Every Drug Database in the Country
There's no single ID for 'ibuprofen' across government databases. RxNorm solves that by assigning each drug a universal concept identifier.
Adverse EventsNov 2025
The Difference Between an Adverse Event and a Side Effect
These terms get used interchangeably, but they mean different things. An adverse event is any bad outcome reported after taking a drug, whether or not the drug caused it.
PolicyOct 2025
Drug Pricing Transparency: What's Changed Since 2022
Recent federal rules now require hospitals and insurers to publish negotiated prices. How that data is shaping public awareness of drug costs.
FDA ProcessOct 2025
Why Some Drugs Get Approved Faster Than Others
The FDA has several accelerated approval pathways for serious conditions. Breakthrough therapy, fast track, and priority review each work differently.
Open DataSep 2025
Open Government Data Is Only Useful If People Can Actually Find It
The FDA, NIH, and CDC maintain dozens of public databases. The problem isn't access, it's discoverability. Most people don't know these resources exist.